Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Testen van de toevoeging van een geneesmiddel tegen kanker, ZEN003694, aan de gebruikelijke chemotherapiebehandeling (capecitabine) voor gemetastaseerde of inoperabele kankers

27 oktober 2026 bijgewerkt door: National Cancer Institute (NCI)

Fase I-studie van ZEN003694 (ZEN-3694) in combinatie met capecitabine bij patiënten met solide tumoren

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.

Studie Overzicht

Gedetailleerde beschrijving

PRIMARY OBJECTIVE:

I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.

II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.

III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).

IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.

OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.

Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • California
      • Irvine, California, Verenigde Staten, 92612
        • Werving
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Contact:
        • Hoofdonderzoeker:
          • Fa-Chyi Lee
      • Orange, California, Verenigde Staten, 92868
        • Werving
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Fa-Chyi Lee
    • Florida
      • Gainesville, Florida, Verenigde Staten, 32610
        • Werving
        • UF Health Cancer Institute - Gainesville
        • Contact:
        • Hoofdonderzoeker:
          • Thomas J. George
    • Illinois
      • Shiloh, Illinois, Verenigde Staten, 62269
        • Actief, niet wervend
        • Memorial Hospital East
    • Kansas
      • Fairway, Kansas, Verenigde Staten, 66205
        • Werving
        • University of Kansas Clinical Research Center
        • Contact:
        • Hoofdonderzoeker:
          • Joaquina C. Baranda
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • University of Kansas Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Joaquina C. Baranda
      • Westwood, Kansas, Verenigde Staten, 66205
        • Werving
        • University of Kansas Hospital-Westwood Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Joaquina C. Baranda
    • Missouri
      • City of Saint Peters, Missouri, Verenigde Staten, 63376
        • Actief, niet wervend
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Verenigde Staten, 63141
        • Actief, niet wervend
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Verenigde Staten, 63110
        • Actief, niet wervend
        • Washington University School of Medicine
      • St Louis, Missouri, Verenigde Staten, 63129
        • Actief, niet wervend
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Verenigde Staten, 63136
        • Actief, niet wervend
        • Siteman Cancer Center at Christian Hospital
    • New York
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Ryan Moy
        • Contact:
      • The Bronx, New York, Verenigde Staten, 10461
        • Werving
        • Montefiore Medical Center-Einstein Campus
        • Contact:
        • Hoofdonderzoeker:
          • Chaoyuan Kuang
      • The Bronx, New York, Verenigde Staten, 10467
        • Werving
        • Montefiore Medical Center - Moses Campus
        • Contact:
        • Hoofdonderzoeker:
          • Chaoyuan Kuang
      • The Bronx, New York, Verenigde Staten, 10461
        • Werving
        • Montefiore Medical Center-Weiler Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Chaoyuan Kuang
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • Werving
        • University of Cincinnati Cancer Center-UC Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Davendra P. Sohal
      • West Chester, Ohio, Verenigde Staten, 45069
        • Werving
        • University of Cincinnati Cancer Center-West Chester
        • Contact:
        • Hoofdonderzoeker:
          • Davendra P. Sohal
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Hoofdonderzoeker:
          • Susanna V. Ulahannan
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • Werving
        • UPMC Hillman Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 412-647-8073
        • Hoofdonderzoeker:
          • Anwaar Saeed
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Werving
        • Vanderbilt University/Ingram Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-811-8480
        • Hoofdonderzoeker:
          • Thatcher R. Heumann
      • Nashville, Tennessee, Verenigde Staten, 37204
        • Werving
        • Vanderbilt Breast Center at One Hundred Oaks
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-811-8480
        • Hoofdonderzoeker:
          • Thatcher R. Heumann

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
  • Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
  • Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
  • Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
  • Patients must have measurable disease
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
  • Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
  • Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
  • Absolute neutrophil count >= 1,000/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
  • Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients should be New York Heart Association Functional Classification of class 2B or better
  • The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion Criteria:

  • Previous treatment with BET inhibitors
  • History of inability to tolerate capecitabine at the projected treatment dose on this trial
  • Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
  • Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
  • Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
  • Hepatic tumor burden > 30% or peritoneal carcinomatosis
  • Untreated/uncontrolled central nervous system (CNS) disease
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Severe intercurrent illness or comorbidity
  • Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
  • Patients who are receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
  • Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment (ZEN003694, capecitabine)

Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Undergo biopsy

Andere namen:
  • Bx
  • BIOSY_TYPE
  • Biopsie

Undergo collection of blood samples

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Undergo PET/CT

Andere namen:
  • Medische beeldvorming, positronemissietomografie
  • HUISDIER
  • PET-scan
  • Positron Emissie Tomografie Scan
  • Positron-emissietomografie
  • PT
  • Positronemissietomografie (procedure)

Given PO

Andere namen:
  • Xeloda
  • Ro 09-1978/000

Given PO

Andere namen:
  • BETi ZEN-3694
  • ZEN 3694
  • ZEN-3694
  • ZEN003694

Undergo CT and PET/CT

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of adverse events
Tijdsspanne: Up to 30 days after last dose

Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.

Up to 30 days after last dose
Maximum tolerated dose (MTD)
Tijdsspanne: During the first cycle of therapy (Cycles = 21 days)

Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD.

During the first cycle of therapy (Cycles = 21 days)
Recommended phase 2 dose (RP2D)
Tijdsspanne: Up to 30 days after last dose

Dose level 4 was selected as the RP2D.

Up to 30 days after last dose

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
Tijdsspanne: Up to 12 months

Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD.

Up to 12 months
Progression free survival (PFS)
Tijdsspanne: Up to 12 months

PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions.

Up to 12 months
Objective response rate (ORR)
Tijdsspanne: Up to 12 months

Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals.

Up to 12 months
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
Tijdsspanne: Up to 12 months

Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data.

Up to 12 months
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
Tijdsspanne: Up to 12 months

Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05.

Up to 12 months
Molecular subpopulations particularly sensitized to BETi and capecitabine
Tijdsspanne: Up to 12 months

Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity.

Up to 12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Anwaar Saeed, University of Pittsburgh Cancer Institute LAO

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 november 2023

Primaire voltooiing (Geschat)

30 juni 2027

Studie voltooiing (Geschat)

30 juni 2027

Studieregistratiedata

Eerst ingediend

6 april 2023

Eerst ingediend dat voldeed aan de QC-criteria

6 april 2023

Eerst geplaatst (Werkelijk)

7 april 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren